Intrathecal administration of AAV allowing gene silencing in the brain or the spinal cord has been conducted in ALS (mostly targeting SOD1) with promising results in animal models and its potential was also demonstrated in two patients [105,106]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.